- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Daly Discusses How Clinical Pathways Can Reduce Disparities in Breast Cancer
There can be great disparities across the country and across races when it comes to cancer care, but clinical pathways can help standardize care so everyone gets the most efficacious treatments, said Robert Daly, MD, MBA, medical oncologist, Memorial Sloan Kettering Cancer Center.
There can be great disparities across the country and across races when it comes to cancer care, but clinical pathways can help standardize care so everyone gets the most efficacious treatments, said Robert Daly, MD, MBA, medical oncologist, Memorial Sloan Kettering Cancer Center.
Transcript
How can clinical pathways be used to reduce disparities in cancer care?
Well, I think that is a key way that pathways can be innovative, is how do we reduce these disparities that we know exist? In my own research, I was looking at adjuvant endocrine therapy in breast cancer, which we know is the standard of care for hormone positive breast cancers of certain stages, and we found great disparities across the country and across races as far as administering and prescribing these drugs.
So, I think pathways can help address disparities by standardizing best practices in care. So, it makes sure that all patients who are coming in to an institution or a clinic are getting those treatments that are viewed by the professionals as having the most efficacy for those patients. And that way we kind of standardize the care across the country about what people are getting for the different disease types.
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
Bimekizumab Poised to Tackle Unmet HS Treatment Needs
October 18th 2024Hidradenitis suppurativa (HS) is an inflammatory, chronic disease with very high symptom and physical burdens, and it can get progressively worse over time if it's inadequately treated, explained Amit Garg, MD, founding chair, Department of Dermatology, Northwell Health.
Read More
